Ensign Peak Advisors
VIR icon

Ensign Peak Advisors’s Vir Biotechnology VIR Stock Holding History

Ensign Peak Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.5M Sell
833,779
-237,033
-22% -$2.26M 0.01% 467
2026
Q1 		$9.59M Buy
1,070,812
+539,381
+101% +$4.3M 0.02% 418
2025
Q4 		$3.2M Sell
531,431
-23,550
-4% -$140K 0.01% 611
2025
Q3 		$3.17M Sell
554,981
-28,000
-5% -$143K 0.01% 693
2025
Q2 		$2.94M Buy
582,981
+519,107
+813% +$2.78M 0.01% 782
2025
Q1 		$414K Hold
63,874
– – ﹤0.01% 1594
2024
Q4 		$469K Hold
63,874
– – ﹤0.01% 1616
2024
Q3 		$478K Buy
63,874
+13,600
+27% +$118K ﹤0.01% 1621
2024
Q2 		$447K Hold
50,274
– – ﹤0.01% 1630
2024
Q1 		$509K Sell
50,274
-2,536
-5% -$25.8K ﹤0.01% 1621
2023
Q4 		$531K Buy
52,810
+22,800
+76% +$208K ﹤0.01% 1646
2023
Q3 		$281K Sell
30,010
-147,691
-83% -$2.11M ﹤0.01% 1698
2023
Q2 		$4.36M Hold
177,701
– – 0.01% 626
2023
Q1 		$4.14M Buy
177,701
+63,511
+56% +$1.62M 0.01% 621
2022
Q4 		$2.89M Buy
114,190
+7,350
+7% +$180K 0.01% 698
2022
Q3 		$2.06M Buy
106,840
+38,151
+56% +$970K 0.01% 770
2022
Q2 		$1.75M Sell
68,689
-44,820
-39% -$1.05M ﹤0.01% 856
2022
Q1 		$2.92M Buy
113,509
+2,940
+3% +$87.2K 0.01% 735
2021
Q4 		$4.63M Buy
+110,569
New +$4.33M 0.01% 685
2020
Q4 		– Sell
-24,128
Closed -$829K – 1881
2020
Q3 		$829K Buy
24,128
+18,578
+335% +$800K ﹤0.01% 1385
2020
Q2 		$227K Buy
+5,550
New +$186K ﹤0.01% 1570

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ensign Peak Advisors's VIR Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Vir Biotechnology (VIR) stake by 22% in Q2 2026, selling an estimated $2.26M and leaving 833,779 shares worth $8.5M. The position accounts for 0.01% of the portfolio, ranked #467.

Ensign Peak Advisors first reported a position in VIR in Q2 2020 and has held it in 21 quarters since. The position peaked at $9.59M in Q1 2026. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Ensign Peak Advisors held 833,779 shares of Vir Biotechnology worth $8.5M as of Q2 2026.
  • Ensign Peak Advisors sold 237,033 Vir Biotechnology shares in Q2 2026, an estimated $2.26M.
  • Vir Biotechnology made up 0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #467 holding.
  • Ensign Peak Advisors first reported a position in Vir Biotechnology in Q2 2020 and has held it in 21 quarters since.
  • Ensign Peak Advisors's Vir Biotechnology position peaked at $9.59M in Q1 2026.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.